This is the first post of a new series, that recognizes Myoguide used in scientific publications
We do try to keep track of the many references citing Myoguide use as an essential part of research based publications. This is part of our ongoing surveillance needed and our responsibility maintaining our medical device licences. The following series will feature these articles, to help illustrate the various benefits of using Myoguide in practice and for research applications.
Botulinum Toxin Therapy for Parkinson and Essential Tremor
There have been many journal articles written within the realm of Botulinum Toxin applications that cite “Myoguide” use as part of the studies. The latest one hails out of the Department of Clinical Neurological Sciences, and the Schulich School of Medicine and Dentistry, at University of Western Ontario, as published in Toxins, August 2022.
All injections were administered using needle-EMG guidance, courtesy of the use of the Myoguide System. Injections included the upper-limb muscles in this study investigating clinical outcomes of treating essential tremor (ET) and Parkinson’s disease (PD) tremor, using either clinical, or “kinematic-based” injection pattern determination methods.
The goal was to investigate whether a technology-guided approach can compare with expert clinical assessments (including surface anatomy and palpation).
The net result was that Kinematic-based BoNT-A injections produced similar treatment outcomes to injections based on the clinical expertise of the expert injector.
We posted an article on the “Therapeutic Applications of Botulinum Neurotoxin in Parkinson’s Disease (PD)”, as the eighth article in a series, to address applications of Botulinum neurotoxin (BoNT).
The article presented a short review of therapeutic applications of botulinum neurotoxin in Parkinson’s Disease, with a focus on the benefit of using the Myoguide™ EMG/ESTIM BoNT injection guidance system.
Please have a look at the article and the appropriate reference materials for more details.
Samotus O, Mahdi Y, Jog M. Real-World Longitudinal Experience of Botulinum Toxin Therapy for Parkinson and Essential Tremor. Toxins (Basel). 2022 Aug 17;14(8):557. doi: 10.3390/toxins14080557. PMID: 36006219; PMCID: PMC9413198.
Follow me on linkedIn